Clinical trials: Negative Symptoms of Schizophrenia
Schizophrenia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
- Trial name
- NCT02477670
- Testing
- AVP-786
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Prediabetic State
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and…
- Trial name
- HISTORI (NCT05193578)
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- Denmark
- Volunteers
- 154 people
- Sponsor
- Jan Frystyk
Chronic Cannabis Users, Healthy Subjects
Chronic Cannabis Users: A Model for Negative Symptoms in Schizophrenia
The aim of the current study is set out to find a human model for negative symptoms based on clinical observation that chronic cannabis users express negative symptoms and characterize by the same neurocognitive and…
- Trial name
- NCT01382433
- Testing
- Magnetoencephalograph (MEG), Cambridge Neuropsychological Test Automated Battery (CANTAB)., Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)
- Where
- Israel
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Chronic Schizophrenia
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.
- Trial name
- NCT00148616
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- M. Schaefer, MD
Schizophrenia
Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia
The purpose of this study is to evaluate the effects of a four-week trial of CX516 900mg tid compared to placebo upon verbal memory, attention and negative symptoms.
- Trial name
- CX516 (NCT00235352)
- Testing
- CX516 (Ampakine)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia, Schizoaffective Disorder
Open-label Study of Curcumin C-3 Complex in Schizophrenia
Current evidence suggests that schizophrenia as a serious and complex psychiatric disorder, continues to challenge mental health professionals in their search for better treatment options in the community.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depression
- Trial name
- NCT01875822
- Testing
- Super-Curcumin
- Where
- Puerto Rico
- Volunteers
- 17 people
- Sponsor
- Woodbury, Michel, M.D.
Schizophrenia, Schizoaffective Disorder
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.
- Trial name
- NCT00177580
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia
- Trial name
- NCT02970305
- Testing
- Pimavanserin
- Where
- 101 sites in United States, Bulgaria and 8 more
- Volunteers
- 403 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Animal Assisted Therapy
Efficacy of Equine Assisted Therapy on Negative Symptoms in Patients With Schizophrenia
The main object of this study is to evaluate the efficacy of equine assisted therapy on substantial and so far unsatisfactorily treatable symptom complexes in patients with schizophrenia.
- Trial name
- STABLE (NCT03935243)
- Testing
- equine assisted therapy, activating control phase
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University of Zurich
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Treating Refractory Schizophrenia With rTMS
Symptomatic treatment of the negative symptoms in schizophrenia (such as social withdrawal, affective flattening, poor motivation, and apathy) with medications and psychotherapy are almost non-existent, whereas treatment of the…
- Trial name
- NCT02242578
- Testing
- 1 Hz rTMS, 10 Hz rTMS
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Seton Healthcare Family
Schizophrenia, Cognitive Deficits
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine
The purpose of this study is to attempt to treat cognitive and negative symptoms of schizophrenia, with the nutritional supplement N-acetylcysteine (NAC).
- Conditions
- Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
- Trial name
- NAC2 (NCT02505477)
- Testing
- N-acetylcysteine, Treatment as Usual
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women
The aim of the project is to assess the efficacy of Adjunctive Selective Estrogen Receptor Modulators (Raloxifene) on Negative and Cognitive symptoms of Schizophrenia in Postmenopausal Women.
- Trial name
- NCT03418831
- Testing
- Raloxifene Hydrochloride
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Music Therapy Towards Schizophrenia, Negative Symptoms
The Aim of this National study is to examine whether music therapy can reduce negative symptoms and raise Quality of Life for patients suffering from Schizophrenia.
- Trial name
- NCT02942459
- Testing
- Music therapy, Music Listening
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Inge Nygaard Pedersen
Schizophrenia
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
- Trial name
- CONVOKE (NCT05838625)
- Testing
- CT-155, Digital Control
- Where
- 54 sites in United States
- Volunteers
- 464 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia Disorders, Psychotic Disorder
Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial
Schizophrenia is a chronic mental health disorder that affects thoughts, emotions, and behaviors. It includes positive symptoms such as hallucinations and delusions, as well as negative symptoms like reduced motivation, social…
- Trial name
- NCT06838104
- Testing
- Melatonin
- Where
- Pakistan
- Volunteers
- 76 people
- Sponsor
- Lahore General Hospital
Schizophrenia
Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia
This study evaluates the brain correlates of Cognitive Training and Aerobic Exercise in schizophrenia. A third of participants will receive Cognitive Training plus Standard Care for schizophrenia.
- Trial name
- CORTEX-SP (NCT03509597)
- Testing
- Aerobic Exercise, Cognitive Training, Treatment as usual
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Red Salud Mental Araba
Schizophrenia
Schizophrenia Treatment With Photoneuromodulation
Abstract: Randomized clinical trial that aims to see the efficacy of photoneuromodulation for the treatment of negative symptoms of schizophrenia in patients refractory to transcranial direct current stimulation.
- Trial name
- NCT05339347
- Testing
- Photoneuromodulation
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo